GlaxoSmithKline (GSK; NYSE: GSK), the UK-based pharmaceutical giant, is facing legal action in the form of a whistleblower lawsuit filed by Valisure, a US-based chemical analysis company. Valisure alleges that GSK intentionally concealed the carcinogenic link between its popular antacid Zantac (ranitidine) and N-Nitrosodimethylamine (NDMA), a potentially harmful impurity.
The complaint lodged by Valisure suggests that GSK initiated a campaign of misinformation in the 1980s, predicated on allegedly fraudulent publications and testing methods, which contributed to significant financial gains for the company. This lawsuit comes on the heels of a 2020 market withdrawal of all ranitidine drugs in the US, prompted by warnings from Valisure regarding the detection of NDMA in product samples.- Flcube.com
